Research Article
The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population
Table 3
Results of the multivariable linear regression analyses for change in remnant cholesterol when LDL was derived by 3 different methodologies.
| | Friedewald Equation | B | Beta | P Value |
| | Age | –0.21 | –0.10 | 0.708 | | Female | 8.79 | 0.18 | 0.074 | | Diabetes | –5.25 | –0.10 | 0.278 | | ASCVD | 0.87 | 0.01 | 0.913 | | Statin | –2.45 | –0.04 | 0.669 | | Alirocumab 75mg vs evolocumab 140mg | –8.39 | –0.14 | 0.156 | | Alirocumab 150mg vs evolocumab 140mg | –12.09 | –0.21 | 0.036 | | Triglyceride group (high vs low) | –20.06 | –0.41 | <0.001 |
| | Direct Measurement | | | |
| | Age | –0.31 | –0.14 | 0.193 | | Female | 8.39 | 0.16 | 0.113 | | Diabetes | –1.61 | –0.03 | 0.757 | | ASCVD | 2.90 | 0.04 | 0.734 | | Statin | –8.60 | –0.14 | 0.165 | | Alirocumab 75mg vs evolocumab 140mg | –1.56 | –0.03 | 0.806 | | Alirocumab 150mg vs evolocumab 140mg | –7.29 | –0.12 | 0.236 | | Triglyceride group (high vs low) | –16.29 | –0.32 | 0.001 |
| | Martin/Hopkins Method | | | |
| | Age | –0.27 | –0.14 | 0.185 | | Female | 8.62 | 0.19 | 0.053 | | Diabetes | –4.16 | –0.09 | 0.342 | | ASCVD | 1.15 | 0.02 | 0.872 | | Statin | –0.87 | –0.02 | 0.866 | | Alirocumab 75mg vs evolocumab 140mg | –6.04 | –0.11 | 0.259 | | Alirocumab 150mg vs evolocumab 140mg | –12.76 | –0.24 | 0.015 | | Triglyceride group (high vs low) | –16.76 | –0.38 | <0.001 |
|
|
ASCVD = atherosclerotic cardiovascular disease.
|
